0000899243-22-016336.txt : 20220503
0000899243-22-016336.hdr.sgml : 20220503
20220503164733
ACCESSION NUMBER: 0000899243-22-016336
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220501
FILED AS OF DATE: 20220503
DATE AS OF CHANGE: 20220503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCGLYNN MARGARET G
CENTRAL INDEX KEY: 0001215126
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 22887832
MAIL ADDRESS:
STREET 1: C/O MERCK & CO INC
STREET 2: ONE MERCK DRIVE PO BOX 100
CITY: WHITEHOUSE STATION
STATE: NJ
ZIP: 08889-0100
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-01
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001215126
MCGLYNN MARGARET G
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
0
0
0
Common Stock
2022-05-01
4
D
0
921
D
178
D
Deferred Stock Units
2022-05-01
4
A
0
921
A
Common Stock
921
5609
D
Stock Option (Right to Buy)
276.17
2022-05-01
4
A
0
4462
0.00
A
2022-05-01
2032-04-30
Common Stock
4462
4462
D
Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units.
Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death.
/s/ Sabrina Yohai, Attorney-in-Fact
2022-05-03